Skip to main content
. 2019 Apr 1;11(4):151. doi: 10.3390/pharmaceutics11040151

Figure 2.

Figure 2

(A) Integrin αvβ3 binding affinity of conjugates 10 and 11 compared to the free ligand (9). (B) Plasma stability of conjugate 10 in mouse and human plasma. (C) Plasma stability of conjugate 11 in mouse and human plasma. (D) Metabolism of conjugate 10 in mouse plasma and the release of cryptophycin-55 glycinate (4). Data points are averages of three experiments, error bars indicate SD.